Biotech Lock-Up Expiration Hell Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (599)	1/24/2002 4:22:07 PM
From: Extra Pale	Read Replies (1) of 1005

Tuck, "GenVec had crawled into purgatory, but now it's back to Hell." Surprisingly, fell 'only' 10% on very heavy volume - so maybe gnvc is now in purgatory's basement. -g- Management spin is that Pfizer has such a deep pipeline that they had to cut something loose; and since Pfizer is focused on small molecules - gene therapy product did not fit. Management also stated that they do not intend to change this years plans regarding TNFerade or other planned trials. Additionally, after BioBypass Phase 2 results are reported late this year, gnvc will be in a great position to negotiate new partnership for non-u.s. rights (gnvc to retain u.s. market). Looks to me as tho gnvc may linger for a long time in blue hell due to future funding requirements.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next